Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF

Highlights

• Omecamtiv mecarbil (OM) demonstrated consistent clinical benefits in reducing cardiovascular death or first heart failure events across the entire age spectrum (18–85 years).
• The treatment effect was particularly robust in patients with severe heart failure, regardless of whether they were under or over 65 years of age.
• Unlike many traditional inotropes, OM showed no significant interaction with age regarding safety outcomes, including blood pressure and heart rate stability.
• In the GALACTIC-HF trial, more than half of the participants (54.5%) were aged 65 or older, providing high-quality evidence for geriatric heart failure management.

Background